Skip to Main Content

Advertisement

Skip Nav Destination

In vitro sensitivity data suggests targeting several tumor types and molecular subtypes with the PI3K inhibitor GSK1059615 could maximize response rates in early clinical trials

Clin Cancer Res (2008) 14 (19_Supplement): B37.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal